含有埃鲁的基托桑涂层固体脂质混合纳米颗粒:一种高效的药物递送系统,可增强溶解性和持续释放性
Nakul Bhardwaj1, Akshay Kumar1, Prabhjot Kaur2
1Department of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India.
International journal of biological macromolecules
|March 26, 2025
概括
素涂层脂质聚合物混合纳米颗粒 (ER-LPHNPs) 显著增强.
科学领域:
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
背景情况:
- 埃鲁是Eruca sativa种子中的脂性化合物,具有治疗潜力,但具有较差的溶解性和生物可用性.
- 开发有效的药物输送系统对于克服这些局限性和利用erucin的好处至关重要.
研究的目的:
- 开发和表征酸盐涂层脂质聚合物混合纳米粒子 (ER-LPHNPs) 以提高溶解度,生物可用性和持续释放的素.
- 评估开发的ER-LPHNP的体外和体内性能,包括毒性和葡萄糖吸收.
主要方法:
- 使用HR-TEM,FE-SEM,AFM,FTIR以及粒子大小/PDI/ZP分析优化和描述ER-LPHNP.
- 试验室研究包括封装效率,持续释放特征,RAW 264.7细胞和面包酵母的毒性测定,面包酵母和L6细胞的葡萄糖吸收测定.
- 在体内进行了药理动力学研究,以评估与悬浮制剂相比的生物可用性,Cmax和Tmax.
主要成果:
- 优化的ER-LPHNP表现出球形形态,理想尺寸 (~112 nm),PDI (0.244),和正ZP (+33.6 mV) 的封装效率> 90%.
- 在pH 7.4时观察到持续释放的素,FTIR证实没有药物辅助物相互作用.
- ER-LPHNP对酵母和RAW 264.7细胞无毒性,在L6细胞显著增强葡萄糖吸收,并在体内增加了256%的erucin生物可用性.
结论:
- 素涂层脂质聚合物混合纳米颗粒代表了埃鲁的有前途的纳米输送系统.
- ER-LPHNP有效地解决了溶解性,生物可用性和持续释放的挑战,为改善治疗应用提供了潜力.
相关概念视频
Factors Affecting Dissolution: Particle Size and Effective Surface Area
655
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
655
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
162
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
162


